A systematic review of counterfeit and substandard medicines in field quality surveys

References

• Waller P. Pharmacoepidemiology – a tool for public health. Pharmacoepidemiol Drug Saf. 2001;10(2):165–172.
   Web of Science ®Google Scholar
• Amin AA, Snow RW, Kokwaro GO. The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector. J Clin Pharm Ther. 2005;30(6):559–565.
   Web of Science ®Google Scholar
• World Health Organization. Counterfeit Drugs. Geneva: World Health Organization; 1999. Available from: http://whqlibdoc.who.int/hq/1999/WHO_EDM_QSM_99.1.pdf. Accessed May 16, 2013.
   Google Scholar
• World Health Organization. Substandard and Counterfeit Medicines. Geneva: World Health Organization; 2003. Available from http://www.who.int/mediacentre/factsheets/2003/fs275/en/. Accessed May 10, 2012.
   Google Scholar
• World Health Organization. What Are Substandard Medicines? Geneva: World Health Organization; 2014. Available from: http://www.who.int/medicines/services/counterfeit/faqs/06/en/. Accessed February 8, 2014.
   Google Scholar
• USP council of convention section on global public health; USP council of experts international health expert committee; USP regionalization team, Heyman ML, Williams RL. Ensuring global access to quality medicines: role of the US Pharmacopeia. J Pharm Sci. 2011;100(4):1280–1287.
   Google Scholar
• Yankus W, Marks S. Counterfeit Drugs: Coming to a Pharmacy Near You with an Update for 2009. New York: American Council on Science and Health; 2009. Available from: http://acsh.org/2006/08/counterfeit-drugs-coming-to-a-pharmacy-near-you-2/. Accessed November 15, 2011.
   Google Scholar
• Wertheimer AI, Norris J. Safeguarding against substandard/counterfeit drugs: mitigating a macroeconomic pandemic. Res Social Adm Pharm. 2009;5(1):4–16.
   PubMed Web of Science ®Google Scholar
• Clift C. Combating Counterfeit, Falsified and Substandard Medicines: Defining the Way Forward? London: Chatham House; 2010. Available from: http://www.chathamhouse.org/sites/default/files/public/Research/Global%20Health/1110bp_counterfeit.pdf. Accessed October 15, 2011.
   Google Scholar
• Deats M, Bourdillon-Esteve P. Substandard, Spurious, Falsely Labelled, Falsified and Counterfeit (SSFFC) Medical Products: Global Surveillance and Monitoring Project. Geneva: World Health Organization; 2013. Available from: http://www.who.int/medicines/technical_briefing/tbs/WHO_HQ_TBS_Oct_2013.pdf. Accessed February 8, 2014.
   Google Scholar
• Newton PN, Lee SJ, Goodman C, et al. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med. 2009;6(3):e52.
   Web of Science ®Google Scholar
• Newton PN, Amin AA, Bird C, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med. 2011; 8(12):e1001139.
   PubMed Web of Science ®Google Scholar
• Amin AA, Kokwaro GO. Antimalarial drug quality in Africa. J Clin Pharm Ther. 2007;32(5):429–440.
   Web of Science ®Google Scholar
• World Health Organization. International Medical Products Anti-Counterfeiting Taskforce – IMPACT. Geneva, World Health Organization; 2011. Available from: http://www.who.int/impact/en/. Accessed February 8, 2014.
   Google Scholar
• Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2(4):e100.
   PubMed Web of Science ®Google Scholar
• Mackey TK, Liang BA. The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci. 2011;100(11):4571–4579.
   PubMed Web of Science ®Google Scholar
• Kao SL, Chan CL, Tan B, et al. An unusual outbreak of hypoglycemia. N Engl J Med. 2009;360(7):734–736.
   PubMed Web of Science ®Google Scholar
• Lühn S, Schiemann S, Alban S. Simple fluorescence assay for quantification of OSCS in heparin. Anal Bioanal Chem. 2011;399(2):673–680.
   PubMed Web of Science ®Google Scholar
• Davison M. Pharmaceutical Anti-Counterfeiting Combating the Real Danger from Fake Drugs. New Jersey: John Wiley & Sons Inc.; 2011.
   Google Scholar
• Holzgrabe U, Malet-Martino M. Analytical challenges in drug counterfeiting and falsification – The NMR approach. J Pharm Biomed Anal. 2011;55(4):679–687.
   Web of Science ®Google Scholar
• Moken MC. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices. Am J Law Med. 2003;29(4):525–542.
   Web of Science ®Google Scholar
• Ziance RJ. Roles for pharmacy in combatting counterfeit drugs. J Am Pharm Assoc (2003). 2008;48(4):e71–e88.
   Google Scholar
• Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health. 2008;13(8):1062–1072.
   PubMed Web of Science ®Google Scholar
• Fried M. Is this pill safe? Substandard medicines, mistaken solutions. CMAJ. 2011;183(8):984.
   Web of Science ®Google Scholar
• Newton PN, Green MD, Fernández FM, Day NPJ, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6(9):602–613.
   PubMed Web of Science ®Google Scholar
• Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012;12(6):488–496.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother. 2007;60(2):214–236.
   PubMed Web of Science ®Google Scholar
• Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open. 2013;3(8):e002923.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis. 2013;17(3):308–311.
   PubMed Web of Science ®Google Scholar
• Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S. Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana. BMJ Open. 2012;2(3):e000431.
   Web of Science ®Google Scholar
• Baratta F, Germano A, Brusa P. Diffusion of counterfeit drugs in developing countries and stability of galenics stored for months under different conditions of temperature and relative humidity. Croat Med J. 2012;53(2):173–184.
   Web of Science ®Google Scholar
• Nair A, Strauch S, Lauwo J, Jähnke RW, Dressman J. Are counterfeit or substandard anti-infective products the cause of treatment failure in Papua New Guinea? J Pharm Sci. 2011;100(11):5059–5068.
   Web of Science ®Google Scholar
• Ali SA, Ezika CC, Abdulraheem OR, et al. Quality assessment of Artemisinin-based drugs marketed and used in Maiduguri Metropolitan Council Borno State, Nigeria. Res J Pharm Biol Chem Sci. 2011;2(2):615–623.
   Google Scholar
• Khan MH, Okumura J, Sovannarith T, Nivanna N, Akazawa M, Kimura K. Prevalence of counterfeit anthelminthic medicines: a cross-sectional survey in Cambodia. Trop Med Int Health. 2010;15(5):639–644.
   Web of Science ®Google Scholar
• Ochekpe NA, Agbowuro AA, Attah SE. Correlation of price and quality of medicines: assessment of some artemisinin antimalarials in Nigeria based on GPHF minilab. Int J Drug Dev Res. 2010;2(1):211–218.
   Google Scholar
• Bate R, Tren R, Mooney L, et al. Pilot study of essential drug quality in two major cities in India. PLoS ONE. 2009;4(6):e6003.
   Web of Science ®Google Scholar
• Onwujekwe O, Kaur H, Dike N, et al. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J. 2009;8(1):22.
   Google Scholar
• Risha PG, Msuya Z, Clark M, Johnson K, Ndomondo-Sigonda M, Layloff T. The use of Minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience. Health Policy. 2008;87(2):217–222.
   Web of Science ®Google Scholar
• Tipke M, Diallo S, Coulibaly B, et al. Substandard anti-malarial drugs in Burkina Faso. Malar J. 2008;7(1):95.
   Google Scholar
• Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa – a six country study. PLoS ONE. 2008;3(5):e2132.
   Web of Science ®Google Scholar
• Pouillot R, Bilong C, Boisier P, et al. Le circuit informel des médicaments à Yaoundé et à Niamey : étude de la population des vendeurs et de la qualité des médicaments distribués. [Illicit drug trade on the markets of Yaounde (Cameroon) and Niamey (Niger): characteristics of salesmen and quality of drugs]. Bull Soc Pathol Exot. 2008;101(2):113–118. French.
   Google Scholar
• Ofori-Kwakye K, Asantewaa Y, Gaye O. Quality of artesunate tablets sold in pharmacies in Kumasi, Ghana. Trop J Pharm Res. 2008;7(4):1179–1184.
   Web of Science ®Google Scholar
• Atemnkeng MA, Chimanuka B, Plaizier-Vercammen J. Quality evaluation of chloroquine, quinine, sulfadoxine-pyrimethamine and proguanil formulations sold on the market in East Congo DR. J Clin Pharm Ther. 2007;32(2):123–132.
   PubMed Web of Science ®Google Scholar
• Gaudiano MC, Di Maggio A, Cocchieri E, et al. Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials. Malar J. 2007;6(1):22.
   Google Scholar
• Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health. 2007;12(1):68–74.
   PubMed Web of Science ®Google Scholar
• Syhakhang L, Freudenthal S, Tomson G, Wahlström R. Knowledge and perceptions of drug quality among drug sellers and consumers in Lao PDR. Health Policy Plan. 2004;19(6):391–401.
   Web of Science ®Google Scholar
• Basco LK. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg. 2004;70(3):245–250.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health. 2004;9(12):1241–1246.
   PubMed Web of Science ®Google Scholar
• Prazuck T, Falconi I, Morineau G, Bricard-Pacaud V, Lecomte A, Ballereau F. Quality control of antibiotics before the implementation of an STD program in Northern Myanmar. Sex Transm Dis. 2002;29(11):624–627.
   Web of Science ®Google Scholar
• Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet. 2001;357(9272):1933–1936.
   PubMed Web of Science ®Google Scholar
• Stenson B, Lindgren BH, Syhakhang L, Tomson G. The quality of drugs in private pharmacies in the Lao People’s Democratic Republic. Int J Risk Saf Med. 1998;11(4):243–249.
   Google Scholar
• Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997;2(9):839–845.
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Eggelte TA, de Vries PJ, Beijnen JH. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst (Lond). 2012;137(5):1265–1274.
   PubMed Web of Science ®Google Scholar
• Sengaloundeth S, Green MD, Fernández FM, et al. A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR – implications for therapeutic failure and drug resistance. Malar J. 2009;8(1):172.
   Google Scholar
• Newton PN, Fernández FM, Plançon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med. 2008;5(2):e32.
   Web of Science ®Google Scholar
• Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet. 2001;357(9272):1948–1950.
   Web of Science ®Google Scholar
• Said MM, Gibbons S, Moffat AC, Zloh M. Near-infrared spectroscopy (NIRS) and chemometric analysis of Malaysian and UK paracetamol tablets: a spectral database study. Int J Pharm. 2011;415(1–2):102–109.
   Google Scholar
• Haruna B, Adaku OE, Usifoh CO. Chemical equivalence study on four brands of α-methyldopa. J Chem Pharm Res. 2013;5(10):356–358.
   Google Scholar
• Audu SA, Taiwo AE, Saidu KO, et al. Quantitative analysis of ten (10) different brands of chlorpheniramine tablet marketed in Maiduguri metropolitan council (MMC). J Chem Pharm Res. 2012;4(7):3637–3650.
   Google Scholar
• Ramachandran G, Chandrasekaran V, Hemanth Kumar AK, Dewan P, Swaminathan S, Thomas A. Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India. Trop Med Int Health. 2013;18(9):1141–1144.
   Web of Science ®Google Scholar
• Khan MH, Hatanaka K, Sovannarith T, et al. Effects of packaging and storage conditions on the quality of amoxicillin-clavulanic acid – An analysis of Cambodian samples. BMC Pharmacol Toxicol. 2013;14:33.
   Web of Science ®Google Scholar
• Affum AO, Lowor S, Osae SD, Dickson A, Gyan BA, Tulasi D. A pilot study on quality of artesunate and amodiaquine tablets used in the fishing community of Tema, Ghana. Malar J. 2013; 12(1):220.
   Google Scholar
• Briesen S, Guthoff R, Kilangalanga N, Mundkowski RG. Counterfeiting von Augentropfen?: Eine Untersuchung von Antibiotikapräparaten aus 2 Ländern Afrikas. [Counterfeiting of eye drops?: a laboratory study of antibiotic eye drops purchased in two African countries]. Ophthalmologe. 2012;109(12):1207–1210. German.
   Google Scholar
• Nogueira FH, Moreira-Campos LM, Santos RL, Pianetti GA. Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the Brazilian Health System. Rev Soc Bras Med Trop. 2011;44(5):582–586.
   Web of Science ®Google Scholar
• El-Duah M, Ofori-Kwakye K. Substandard artemisinin-based antimalarial medicines in licensed retail pharmaceutical outlets in Ghana. J Vector Borne Dis. 2012;49(3):131–139.
   PubMed Web of Science ®Google Scholar
• Karlage KL, Franklin SJ, Mufich WC, et al. Comparative evaluation of pharmaceutical products obtained in Mexico: augmenting existing scientific data. Drug Dev Ind Pharm. 2012;38(7):808–814.
   PubMed Web of Science ®Google Scholar
• Pribluda VS, Barojas A, Añez A, et al. Implementation of basic quality control tests for malaria medicines in Amazon Basin countries: results for the 2005–2010 period. Malar J. 2012;11(1):202.
   Google Scholar
• Klein EY, Lewis IA, Jung C, Llinás M, Levin SA. Relationship between treatment-seeking behaviour and artemisinin drug quality in Ghana. Malar J. 2012;11(1):110.
   Google Scholar
• Ehianeta T, Williams B, Surakat J, Mohammed N, Anyakora C. Quality survey of some brands of artesunate-amodiaquine in Lagos drug market. Afr J Pharm Pharmacol. 2012;6:636–642.
   Google Scholar
• Bate R, Jin GZ, Mathur A. Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Econ. 2011;30(6):1150–1163.
   PubMed Web of Science ®Google Scholar
• Seear M, Gandhi D, Carr R, Dayal A, Raghavan D, Sharma N. The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India. J Clin Pharm Ther. 2011;36(4):488–495.
   Web of Science ®Google Scholar
• Akpabio E, Jackson C, Ugwu C, Etim M, Udofia M. Quality control and in vitro bioequivalence studies on four brands of ciprofloxacin tablets commonly sold in Uyo Metropolis, Nigeria. J Chem Pharm Res. 2011;3(3):734–741.
   Google Scholar
• Hadi U, van den Broek P, Kolopaking EP, Zairina N, Gardjito W, Gyssens IC; Study Group Antimicrobial Resistance in Indonesia: Prevalence and Prevention AMRIN. Cross-sectional study of availability and pharmaceutical quality of antibiotics requested with or without prescription (Over The Counter) in Surabaya, Indonesia. BMC Infect Dis. 2010;10(1):203.
   PubMedGoogle Scholar
• Bate R, Hess K. Anti-malarial drug quality in Lagos and Accra – A comparison of various quality assessments. Malar J. 2010;9(1):157.
   Google Scholar
• Leslie T, Kaur H, Mohammed N, Kolaczinski K, Ord RL, Rowland M. Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. Emerg Infect Dis. 2009;15(11):1753–1759.
   Web of Science ®Google Scholar
• Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet C, Van Bortel L. Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg. 2009;81(5):776–781.
   Web of Science ®Google Scholar
• Obaid A. Quality of ceftriaxone in Pakistan: reality and resonance. Pak J Pharm Sci. 2009;22(2):220–229.
   Web of Science ®Google Scholar
• Bate R, Tren R, Hess K, Mooney L, Porter K. Pilot study comparing technologies to test for substandard drugs in field settings. African Journal of Pharmacy and Pharmacology. 2009;3(4):165–170.
   Google Scholar
• Fotiou F, Aravind S, Wang PP, Nerapusee O. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther. 2009;31(2):336–346.
   Web of Science ®Google Scholar
• Kaur H, Goodman C, Thompson E, et al. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS ONE. 2008;3(10):e3403.
   Web of Science ®Google Scholar
• Kyriacos S, Mroueh M, Chahine RP, Khouzam O. Quality of amoxicillin formulations in some Arab countries. J Clin Pharm Ther. 2008;33(4):375–379.
   Web of Science ®Google Scholar
• Meos A, Paap M, Matto V, Veski P. Comparative evaluation of quality of doxycycline formulations registered in Estonia to those registered in the Russian Federation. Drug Dev Res. 2008;69(2):58–68.
   Web of Science ®Google Scholar
• Bronnikova O, Matto V, Meos A. Comparative study of amoxicillin formulations registered in Estonia to those produced in Russia. Eur J Pharm Sci. 2007;32(Suppl 1):S50.
   Web of Science ®Google Scholar
• Vijaykadga S, Cholpol S, Sitthimongkol S, et al. Strengthening of national capacity in implementation of antimalarial drug quality assurance in Thailand. Southeast Asian J Trop Med Public Health. 2006;37(3)(Suppl 3):5–10.
   Google Scholar
• Lon CT, Tsuyuoka R, Phanouvong S, et al. Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg. 2006;100(11):1019–1024.
   PubMed Web of Science ®Google Scholar
• Abdo-Rabbo A, Bassili A, Atta H. The quality of antimalarials available in Yemen. Malar J. 2005;4(1):28.
   Google Scholar
• Rookkapan K, Chongsuvivatwong V, Kasiwong S, Pariyawatee S, Kasetcharoen Y, Pungrassami P. Deteriorated tuberculosis drugs and management system problems in lower southern Thailand. Int J Tuberc Lung Dis. 2005;9(6):654–660.
   Web of Science ®Google Scholar
• Kayumba PC, Risha PG, Shewiyo D, et al. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J Clin Pharm Ther. 2004;29(4):331–338.
   Web of Science ®Google Scholar
• Minzi OMS, Moshi MJ, Hipolite D, et al. Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. J Clin Pharm Ther. 2003;28(2):117–122.
   PubMed Web of Science ®Google Scholar
• Obodozie OO, Mustapha KB, Ebeshi BU, Inyang US. A comparative study on the prevalence of substandard ampicillin/cloxacillin preparations in the Nigerian market: Mid 1990’s and present. J Phytomed Therapeutics. 2006;11:1–8.
   Google Scholar
• Laserson KF, Kenyon AS, Kenyon TA, Layloff T, Binkin NJ. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis. 2001;5(5):448–454.
   PubMed Web of Science ®Google Scholar
• Kenyon TA, Kenyon AS, Kgarebe BV, Mothibedi D, Binkin NJ, Layloff TP. Detection of substandard fixed-dose combination tuberculosis drugs using thin-layer chromatography. Int J Tuberc Lung Dis. 1999;3(11)(suppl 3):S347–S350, discussion S351–S352.
   Web of Science ®Google Scholar
• World Health Organization. Assessment of Medicines Regulatory Systems in Sub-Saharan African Countries: An Overview of Findings from 26 Assessment Reports. Geneva: World Health Organization; 2010. Available from: http://apps.who.int/medicinedocs/documents/s17577en/s17577en.pdf. Accessed January 3, 2014.
   Google Scholar
• McGinnis M. Media Reports on Medicine Quality: Focusing on USAID-Assisted Countries. Rockville, MD: United States Pharmacopeia; 2013. Available from: http://www.usp.org/sites/default/files/usp_pdf/EN/media_reports-2013-october.pdf. Accessed January 4, 2014.
   Google Scholar
• World Health Organization. Report of the Situation of Counterfeit Medicines Based on Data Collection Tool: WHO Regions for Africa and Eastern Mediterranean. Geneva: World Health Organization; 2010. Available from: http://www.who.int/medicines/services/expertcommittees/pharmprep/WHO-ACM-3IMPACTSurveyDataCollectionToolReport.pdf. Accessed January 3, 2014.
   Google Scholar
• World Health Organization. Noncommunicable Diseases. Geneva: World Health Organization; 2013. Available from: http://www.who.int/mediacentre/factsheets/fs355/en/. Accessed July 31, 2013.
   Google Scholar
• World Health Organization. Contaminated Isotab^® (Isosorbide Mononitrate) Incident in Lahore Pakistan. Geneva: World Health Organization; 2012. Available from: http://www.who.int/medicines/publications/drugalerts/DrugSafetyAlert125.pdf. Accessed August 28, 2013.
   Google Scholar
• Nishtar S. Pakistan’s deadly cocktail of substandard drugs. Lancet. 2012;379(9821):1084–1085.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Avastin (bevacizumab): Counterfeit Product – FDA Issues Letters to 19 Medical Practices. Washington, DC: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm291968.htm. Accessed January 4, 2014.
   Google Scholar
• US Food and Drug Administration. Altuzan (bevacizumab): Counterfeit Product – Contains No Active Ingredient. Washington, DC: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm298583.htm. Accessed January 4, 2014.
   Google Scholar
• World Health Organization. Medicines: Spurious/Falsely-Labelled/ Falsified/Counterfeit (SFFC) Medicines. Geneva: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs275/en/. Accessed July 20, 2013.
   Google Scholar
• Lung DD, Gerona RR, Wu AH, Smollin CG. Confirmed glyburide poisoning from ingestion of “street Valium”. J Emerg Med. 2012;43(2):276–278.
   Web of Science ®Google Scholar
• International Pharmaceutical Federation. Tool for Visual Inspection of Medicines. The Hague: International Pharmaceutical Federation; 2013. Available from: https://www.fip.org/files/fip/counterfeit/VisualInspection/A%20tool%20for%20visual%20inspection%20of%20medicines%20EN.pdf. Accessed: May 25, 2013.
   Google Scholar
• Pharmaceutical Security Institute. Incident Trends. Vienna, VA, USA: Pharmaceutical Security Institute; 2012. Available from: http://www.psi-inc.org/incidentTrends.cfm. Retrieved April 14, 2012.
   Google Scholar
• Gebran N, Al Haidari K. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia. Ann Saudi Med. 2006;26(3):192–199.
   Web of Science ®Google Scholar
• Al-Aqeel SA. Evaluation of medication package inserts in Saudi Arabia. Drug Healthc Patient Saf. 2012;4:33–38.
   Google Scholar